Results 291 to 300 of about 1,144,970 (369)

Alpha-synuclein co-pathology in Down syndrome-associated Alzheimer's disease. [PDF]

Alzheimers Dement
Bernhardt AM, Rodríguez-Baz Í, Aldecoa I, Arranz J, Arriola-Infante JE, Maure-Blesa L, Carmona-Iragui M, Longen S, Trossbach SV, Giese A, Matthias T, Benejam B, Videla L, Del Hoyo Soriano L, Barroeta I, Sanjuan A, Fernández S, Vaqué-Alcázar L, Rozalem Aranha M, Morcillo-Nieto AO, Nübling G, Wagemann O, Stockbauer A, Tondo M, Bejanin A, Lleó A, Alcolea D, Molina-Porcel L, Fortea J, Levin J.   +29 more
europepmc   +1 more source

Nano‐Biosensors for Continuous Cognitive and Stress Monitoring: Applications in Learning and Mental Well‐Being

Nano Select, EarlyView.
Nano‐biosensors offer real‐time monitoring of cognitive and emotional states through biomarkers like cortisol and dopamine. They enhance personalized learning, mental health interventions, and daily performance across sectors. Integrated into wearables and IoT, they promise a transformative impact while raising ethical, technological, and regulatory ...
Priscilla Adomako Gyasi, Jesse Nii Okai Amu‐Darko, Binghai Sun, Eliasu Issaka, Seth Yeboah Ntim, Michael Enyan, Shahid Hussain   +6 more
wiley   +1 more source

Divalent and Trivalent Metallic Ions Differentially Affect Alpha-Synuclein Aggregation. [PDF]

ACS Chem Neurosci
Graves NJ, Jaafar AK, Gambin Y, Sierecki E.   +3 more
europepmc   +1 more source

Proteomic Insight Into Alzheimer's Disease Pathogenesis Pathways

PROTEOMICS, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a leading cause of dementia, but the pathogenesis mechanism is still elusive. Advances in proteomics have uncovered key molecular mechanisms underlying AD, revealing a complex network of dysregulated pathways, including amyloid metabolism, tau pathology, apolipoprotein E (APOE), protein degradation ...
Taekyung Ryu, Kyungdo Kim, Nicholas Asiimwe, Chan Hyun Na   +3 more
wiley   +1 more source

Using a stable protein scaffold to display peptides that bind to alpha-synuclein fibrils. [PDF]

Protein Sci
Bismut S, Schneider MM, Miyasaki M, Feng Y, Wilde EJ, Gunawardena MD, Knowles TPJ, Kaminski Schierle GS, Itzhaki LS, Kumita JR.   +9 more
europepmc   +1 more source

Modulation of Alpha-Synuclein Aggregation by Dopamine Analogs

, 2010
Diane Latawiec, Fernando E. Herrera, Alpan Bek, Valeria Losasso, Michela Candotti, Federico Benetti, Elvio Carlino, Agata Kranjc, Marco Lazzarino, Stefano Gustincich, Paolo Carloni, Giuseppe Legname   +11 more
openalex   +2 more sources

Challenges and Opportunities in State‐of‐the‐Art Proteomics Analysis for Biomarker Development From Plasma Extracellular Vesicles

PROTEOMICS, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐bound particles secreted by cells, playing crucial roles in intercellular communication. The composition of EVs can undergo changes in response to stress and disease conditions, making them excellent biomarker candidates.
Panshak P. Dakup, Ivo Diaz Ludovico, Youngki You, Chaitra Rao, Javier Flores, Lisa M. Bramer, Marian Rewers, Bobbie‐Jo M. Webb‐Robertson, Thomas O. Metz, Raghavendra G. Mirmira, Emily K. Sims, Ernesto S. Nakayasu   +11 more
wiley   +1 more source

Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells

, 2010
Kai‐Yin Chau, Jonathan M. Cooper, Anthony H.V. Schapira   +2 more
openalex   +1 more source

Coupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains

PROTEOMICS, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and pathological protein aggregation. Comprehensive quantitative proteomics of brain tissues from AD patients is critical for pursuing a better understanding of the molecular mechanisms that drive AD progression.
Mehrdad Falamarzi Askarani, Fei Fang, Scott E. Counts, Liangliang Sun   +3 more
wiley   +1 more source

Synaptic enrichment of pSer129 alpha-synuclein correlates with dopaminergic denervation in early-stage Parkinson's disease. [PDF]

Nat Commun
Frigerio I, Morella ML, Winkelaar AB, Vorgia DT, Brevé JJ, Boiten WA, van der Gaag BL, Calandri IL, Jonker AJ, Berendse HW, Mona D, Britschgi M, Jonkman LE, van de Berg WD.   +13 more
europepmc   +1 more source